Diabetes is prevailing in pandemic proportions, as nearly half a billion population is affected
by diabetes worldwide. The expenditure on diabetes healthcare is estimated to grow to $845 …

There is an urgent need for effective pharmacological therapies to help tackle the growing
obesity epidemic and the healthcare crisis it poses. The past 3 years have seen approval of …

The glucagon-like peptide-1 (GLP-1) receptor is a key regulator of insulin secretion and a
major therapeutic target for treatment of diabetes. However, GLP-1 receptor function is …

Background: The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment
options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics …

The peptides (PGH) in the< 1 kDa ultrafiltration (UF) fraction of the porcine skin gelatin
hydrolysates obtained by Flavourzyme®(FLA) hydrolysis showed the greatest in vitro …

Incretin-based therapies, including the use of incretin mimetics of glucagon-like peptide-1
receptor (GLP-1R) agonists and incretin enhancers of dipeptidyl-peptidase 4 (DPP-4) …

Aims Epidemiological evidences indicate that individuals with diabetes may have an
increased risk of acute pancreatitis. Therefore, we carried out a meta-analysis to examine …

The pancreas is a dual organ with exocrine and endocrine functions. The interrelationship of
the endocrine-exocrine parts of the pancreas is a complex one, but recent clinical and …

Diabetes mellitus (DM) is a major metabolic disorder currently affecting over 200 million
people worldwide. Approximately 90% of all diabetic patients suffer from Type 2 diabetes …

Exenatide, administered subcutaneously twice daily (Byetta®), is a synthetic version of the
natural peptide exendin-4, which is a glucagon-like peptide-1 (GLP-1) receptor agonist …